EP4704826A1 - Compositions et méthodes destinés à traiter le trouble de stress post-traumatique - Google Patents

Compositions et méthodes destinés à traiter le trouble de stress post-traumatique

Info

Publication number
EP4704826A1
EP4704826A1 EP24798065.9A EP24798065A EP4704826A1 EP 4704826 A1 EP4704826 A1 EP 4704826A1 EP 24798065 A EP24798065 A EP 24798065A EP 4704826 A1 EP4704826 A1 EP 4704826A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
subject
administered
entactogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24798065.9A
Other languages
German (de)
English (en)
Inventor
Alfred KAYE
Christopher PITTENGER
John KRYSTAL
Abigail YU
Axel F. ROSADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
US Department of Veterans Affairs
Original Assignee
Yale University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, US Department of Veterans Affairs filed Critical Yale University
Publication of EP4704826A1 publication Critical patent/EP4704826A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour traiter, améliorer ou prévenir le trouble de stress post-traumatique (TSPT). Les méthodes et compositions thérapeutiques de l'invention comprennent l'utilisation d'au moins un inhibiteur de norépinéphrine et d'au moins un entactogène pour traiter, améliorer ou prévenir le TSPT. Les méthodes et compositions thérapeutiques de l'invention comprennent également l'utilisation d'au moins un agoniste du récepteur adrénergique α2A et d'au moins un agent psychédélique pour traiter, améliorer ou prévenir le TSPT.
EP24798065.9A 2023-04-28 2024-04-26 Compositions et méthodes destinés à traiter le trouble de stress post-traumatique Pending EP4704826A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363499089P 2023-04-28 2023-04-28
PCT/US2024/026542 WO2024226995A1 (fr) 2023-04-28 2024-04-26 Compositions et méthodes destinés à traiter le trouble de stress post-traumatique

Publications (1)

Publication Number Publication Date
EP4704826A1 true EP4704826A1 (fr) 2026-03-11

Family

ID=93257132

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24798065.9A Pending EP4704826A1 (fr) 2023-04-28 2024-04-26 Compositions et méthodes destinés à traiter le trouble de stress post-traumatique

Country Status (4)

Country Link
EP (1) EP4704826A1 (fr)
CN (1) CN121285372A (fr)
AU (1) AU2024263322A1 (fr)
WO (1) WO2024226995A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022529781A (ja) * 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2022212854A1 (fr) * 2021-04-01 2022-10-06 Terran Biosciences Inc. Méthodes et compositions se rapportant à une thérapie psychédélique et à des modulateurs de récepteurs sérotoninergiques
WO2023283386A2 (fr) * 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Compositions psychoactives plus fiables
EP4398871A1 (fr) * 2021-09-08 2024-07-17 Cybin IRL Limited Associations médicamenteuses
US12465578B2 (en) * 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
IL319372A (en) * 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders

Also Published As

Publication number Publication date
CN121285372A (zh) 2026-01-06
AU2024263322A1 (en) 2025-11-13
WO2024226995A1 (fr) 2024-10-31

Similar Documents

Publication Publication Date Title
AU2021382158B2 (en) Mdma prodrugs to assist psychotherapy
US20060199805A1 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP0977558B1 (fr) Utilisation d'antagonistes du recepteur de 5ht4 pour lutter contre les effets gastro-intestinaux d'inhibiteurs de reabsorption de la serotonine
JP2008542378A (ja) 精神病性障害を管理する方法および組成物
EA017443B1 (ru) Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств
WO2006096435A1 (fr) Compositions pharmaceutiques utiles dans le traitement et/ou la prevention de la depression
AU2010211491B2 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
HU229150B1 (hu) Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére
JPWO2011004620A1 (ja) 細胞保護剤
JP2010530867A (ja) うつ病の治療
JPWO2008020651A1 (ja) Ｐ２ｘ４受容体アンタゴニスト
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
EP3556366A1 (fr) Utilisation de composés de carbamate pour la prévention, l'atténuation ou le traitement d'un trouble bipolaire
AU2011214190B2 (en) Use of agomelatine for the preparation of drugs for treating obsessive compulsive disorder (OCD)
WO2024226995A1 (fr) Compositions et méthodes destinés à traiter le trouble de stress post-traumatique
NO335245B1 (no) Anvendelse av alfa-aminoamidderivater med antiinflammatorisk aktivitet for fremstilling av medikamenter
KR20250059489A (ko) 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
WO2026096783A2 (fr) Compositions et méthodes pour le traitement du trouble de stress post-traumatique
JP2005314347A (ja) 疼痛抑制剤
JP2012102069A (ja) 早漏治療剤
KR20190054549A (ko) 말초신경의 나트륨-채널병증을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP2009235069A (ja) ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
KR20250129797A (ko) 글루코오스 수치를 조절하기 위한 조성물 및 방법
WO2025229537A1 (fr) Combinaison pharmaceutique de donépézil et de céviméline

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR